Access cutting-edge glioblastoma treatment through this clinical trial at a research site in Ann Arbor. Study-provided care at no cost to qualified participants.
Access glioblastoma specialists in Ann Arbor at no cost
This study follows strict safety protocols and ethical guidelines
All study-related glioblastoma treatment provided free
The goal of this Phase 3 clinical trial is to compare the efficacy of niraparib versus temozolomide (TMZ) in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma multiforme (GBM). The main questions it aims to answer are: Does niraparib improve progression-free survival (PFS) compared to TMZ? Does niraparib improve overall survival (OS) compared to TMZ? Participants will be randomly assigned to one of two treatment arms: niraparib or TMZ. * study drug (Niraparib) or * comp
Sponsor: Ivy Brain Tumor Center
Check if you qualify for this glioblastoma clinical trial in Ann Arbor, MI
If you're searching for glioblastoma treatment options in Ann Arbor, MI, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Ann Arbor research site is actively enrolling participants for this clinical trial. You'll receive care from experienced glioblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.